Biogen has long been recognized as one of the biotechnology industry’s leading companies, particularly for its treatments targeting neurological diseases. Its portfolio includes established multiple sclerosis therapies such as Tysabri and Tecfidera, as well as Spinraza, a leading treatment for spinal muscular atrophy.

More recently, investor attention has shifted to Leqembi, the Alzheimer’s disease treatment Biogen co-developed with Japanese pharmaceutical company Eisai. As one of the few approved therapies designed to slow cognitive decline in patients with early Alzheimer’s disease, Leqembi represents a significant long-term growth opportunity for the company.

Start pulling in more than a part time job. In about 5-10 min a day you can make more than most sidehustles. Click here to check it out for just $1.

Supporting that outlook, Truist Securities analyst Danielle Brill recently upgraded Biogen from Hold to Buy while raising her price target from $190 to $235. RBC Capital Markets also increased its price target to $242 on July 7. Investors will be watching Biogen’s earnings report on July 29 for updates on Leqembi adoption, pipeline progress, and overall revenue trends.

Sincerely,

Ian Cooper